Last reviewed · How we verify
BL-B01D1
BL-B01D1 is a small molecule drug that targets the SGLT2 receptor.
BL-B01D1 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | BL-B01D1 |
|---|---|
| Also known as | iza-bren, izalontamab brengitecan, BMS-986507, No other name |
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, BL-B01D1 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (PHASE2, PHASE3)
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) (PHASE2, PHASE3)
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy (PHASE2, PHASE3)
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (PHASE1)
- A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer (PHASE2)
- A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors (PHASE2)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BL-B01D1 CI brief — competitive landscape report
- BL-B01D1 updates RSS · CI watch RSS
- Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI